Dexamethasone intravitreal implant (Allergan) for the treatment of noninfectious uveitis

Bibliography

• Addison T. On the constitutional and local effects of disease of the supra-renal capsules. New Sydenham Soc 1868;36:211-39
   Google Scholar
• Hench PS, Kendall EC, Slocumb CH, et al. Effects of cortisone acetate and pituitary ACTH on rheumatoid arthritis, rheumatic fever and certain other conditions. Arch Intern Med (Chic) 1950;85:545-666
   PubMedGoogle Scholar
• Gordon DM, McLean JM, Koteen H. Present status of corticotropin; ACTH, cortisone, and hydrocortisone in ophthalmology. Br J Ophthalmol 1953;37:85-98
   PubMed Web of Science ®Google Scholar
• Gordon DM. Prednisone and prednisolone in ocular disease. Am J Ophthalmol 1956;41:593-600
   PubMed Web of Science ®Google Scholar
• Leopold IH, Sawyer JL, Green H. Intraocular penetration of locally applied steroids. AMA Arch Ophthalmol 1955;54:916-21
   PubMedGoogle Scholar
• Gallant C, Kenny P. Oral glucocorticoids and their complications. A review. J Am Acad Dermatol 1986;14:161-77
   PubMed Web of Science ®Google Scholar
• Schimmer BP, Funder JW. ACTH, adrenal steroids, and pharmacology of the adrenal cortex. In: Brunton LL, Chabner BA, Knollmann BC, editors, Goodman & Gillman's the pharmacological basis of therapeutics. McGraw-Hill, New York; 2011
   Google Scholar
• Melby JC. Clinical pharmacology of systemic corticosteroids. Annu Rev Pharmacol Toxicol 1977;17:511-27
   PubMed Web of Science ®Google Scholar
• Vadot E, Barth E, Billet P. Epidemiology of uveitis- preliminary results of a prospective study in Savoy. In: Saari K, editor, Uveitis update. Elsevier, Amsterdam; 1984. p. 13-16
   Google Scholar
• Miettinen R. Incidence of uveitis in northern finland. Acta Ophthalmol (Copenh) 1977;55:252-60
   PubMed Web of Science ®Google Scholar
• Dandona L, Dandona R, John RK, et al. Population based assessment of uveitis in an urban population in southern India. Br J Ophthalmol 2000;84:706-9
   PubMed Web of Science ®Google Scholar
• Durrani OM, Tehrani NN, Marr JE, et al. Degree, duration, and causes of visual loss in uveitis. Br J Ophthalmol 2004;88:1159-62
   PubMed Web of Science ®Google Scholar
• Rothova A, Suttorp-van Schulten MS, Frits Treffers W, et al. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol 1996;80:332-6
   PubMed Web of Science ®Google Scholar
• Nussenblatt RB. The natural history of uveitis. Int Ophthalmol 1990;14:303-8
   PubMed Web of Science ®Google Scholar
• Suttorp-Schulten MS, Rothova A. The possible impact of uveitis in blindness: a literature survey. Br J Ophthalmol 1996;80:844-8
   PubMed Web of Science ®Google Scholar
• Gritz DC, Wong IG. Incidence and prevalence of uveitis in northern california; the northern california epidemiology of uveitis study. Ophthalmology 2004;111:491-500
   PubMed Web of Science ®Google Scholar
• Wakefield D, Chang JH. Epidemiology of uveitis. Int Ophthalmol Clin 2005;45(2):1-13
   PubMedGoogle Scholar
• Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol 2005;140:509-16
   PubMed Web of Science ®Google Scholar
• Yasukawa T, Ogura Y, Sakurai E, et al. Intraocular sustained drug delivery using implantable polymeric devices. Adv Drug Deliv Rev 2005;57(14):2033-46
   PubMed Web of Science ®Google Scholar
• Kwak HW, D'Amico DJ. Evaluation of the retinal toxicity and pharmacokinetics of dexamethasone after intravitreal injection. Arch Ophthalmol 1992;110:259-66
   PubMed Web of Science ®Google Scholar
• Weijtens O, Schoemaker RC, Romijn FP, et al. Intraocular penetration and systemic absorption after topical application of dexamethasone disodium phosphate. Ophthalmology 2002;109:1887-91
   PubMed Web of Science ®Google Scholar
• Kuppermann BD, Blumenkranz MS, Haller JA, et al. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol 2007;125:309-17
   PubMed Web of Science ®Google Scholar
• Williams GA, Haller JA, Kuppermann BD, et al. Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or irvine-gass syndrome. Am J Ophthalmol 2009;147:1048-54. 1054.e1-2
   PubMed Web of Science ®Google Scholar
• Lowder C, Belfort R Jr, Lightman S, et al. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol 2011;129:545-53
   PubMed Web of Science ®Google Scholar
• Chang-Lin JE, Attar M, Acheampong AA, et al. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci 2011;52:80-6
   PubMed Web of Science ®Google Scholar
• Lightman S, Belfort R Jr, Naik RK, et al. Vision-related functioning outcomes of dexamethasone intravitreal implant in noninfectious intermediate or posterior uveitis. Invest Ophthalmol Vis Sci 2013;54:4864-70
   PubMed Web of Science ®Google Scholar
• Gupta A, Ram J, Gupta A, Gupta V. Intraoperative dexamethasone implant in uveitis patients with cataract undergoing phacoemulsification. Ocul Immunol Inflamm 2013;21(6):462-7
   PubMed Web of Science ®Google Scholar
• Saraiya NV, Patel SS, Goldstein DA. A report of high intraocular pressure with the dexamethasone intravitreal implant. Arch Ophthalmol 2011;129:1638-9; author reply 1639-40
   PubMedGoogle Scholar
• Meyer LM, Schonfeld CL. Secondary glaucoma after intravitreal dexamethasone 0.7 mg implant in patients with retinal vein occlusion: a one-year follow-up. J Ocul Pharmacol Ther 2013;29:560-5
   PubMed Web of Science ®Google Scholar
• Goldstein DA, Godfrey DG, Hall A, et al. Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants. Arch Ophthalmol 2007;125:1478-85
   PubMed Web of Science ®Google Scholar
• Capone A Jr, Singer MA, Dodwell DG, et al. Efficacy and safety of two or more dexamethasone intravitreal implant injections for treatment of macular edema related to retinal vein occlusion (shasta study). Retina 2014;34(2):342-51
   PubMedGoogle Scholar
• Arcinue CA, Cerón OM, Foster CS. A comparison between the fluocinolone acetonide (retisert) and dexamethasone (dexamethasone implant) intravitreal implants in uveitis. J Ocul Pharmacol Ther 2013;29(5):501-7
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Callanan D, Dugel P, et al. Treating chronic noninfectious posterior segment uveitis: the impact of cumulative damage. Proceedings of an expert panel roundtable discussion. Retina 2006;(Suppl):1-16
   PubMed Web of Science ®Google Scholar
• Callanan DG, Jaffe GJ, Martin DF, et al. Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results. Arch Ophthalmol 2008;126:1191-201
   PubMed Web of Science ®Google Scholar
• Kempen JH, Altaweel MM, Holbrook JT, et al. The multicenter uveitis steroid treatment trial: rationale, design, and baseline characteristics. Am J Ophthalmol 2010;149:550-61.e10
   PubMed Web of Science ®Google Scholar
• Kempen JH, Altaweel MM, Holbrook JT, et al. Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial. Ophthalmology 2011;118:1916-26
   PubMed Web of Science ®Google Scholar
• Lai WW, Pulido JS. Intermediate uveitis. Ophthalmol Clin North Am 2002;15:309-17
   PubMedGoogle Scholar
• Forrester JV. Intermediate and posterior uveitis. Chem Immunol Allergy 2007;92:228-43
   PubMedGoogle Scholar
• Kok H, Lau C, Maycock N, et al. Outcome of intravitreal triamcinolone in uveitis. Ophthalmology 2005;112:1916-e1-7
   PubMed Web of Science ®Google Scholar
• Sallam A, Taylor SR, Habot-Wilner Z, et al. Repeat intravitreal triamcinolone acetonide injections in uveitic macular oedema. Acta Ophthalmol 2012;90:e323-5
   PubMed Web of Science ®Google Scholar
• Zaborowski AG. Cytomegalovirus retinitis following intravitreal triamcinolone acetonide in a patient with chronic uveitis on systemic immunosuppression. Ocul Immunol Inflamm 2013;21(2):148-9
   PubMed Web of Science ®Google Scholar
• Vertes D, Snyers B, De Potter P. Cytomegalovirus retinitis after low-dose intravitreous triamcinolone acetonide in an immunocompetent patient: a warning for the widespread use of intravitreous corticosteroids. Int Ophthalmol 2010;30(5):595-7
   PubMedGoogle Scholar
• Tugal-Tutkun I, Araz B, Cagatay A. CMV retinitis after intravitreal triamcinolone acetonide injection in a patient with Behçet's uveitis. Int Ophthalmol 2010;30(5):591-3
   PubMedGoogle Scholar
• Delyfer MN, Rougier MB, Hubschman JP, et al. Cytomegalovirus retinitis following intravitreal injection of triamcinolone: report of two cases. Acta Ophthalmol Scand 2007;85(6):681-3
   PubMedGoogle Scholar
• Shah AM, Oster SF, Freeman WR. Viral retinitis after intravitreal triamcinolone injection in patients with predisposing medical comorbidities. Am J Ophthalmol 2010;149(3):433-40
   PubMedGoogle Scholar
• Ufret-Vincenty RL, Singh RP, Lowder CY, et al. Cytomegalovirus retinitis after fluocinolone acetonide (retisert) implant. Am J Ophthalmol 2007;143(2):334-5
   PubMed Web of Science ®Google Scholar
• Haller JA, Bandello F, Belfort R Jr, et al.; OZURDEX GENEVA Study Group. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010;117(6):1134-46
   PubMed Web of Science ®Google Scholar